{"nctId":"NCT00333788","briefTitle":"Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease","startDateStruct":{"date":"2006-10"},"conditions":["Crohn's Disease"],"count":233,"armGroups":[{"label":"Certolizumab pegol 400 mg","type":"EXPERIMENTAL","interventionNames":["Biological: Certolizumab pegol (CDP870)"]}],"interventions":[{"name":"Certolizumab pegol (CDP870)","otherNames":["CDP870","Cimzia"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients having completed study C87042 \\[NCT00308581\\] (previously treated with infliximab)\n\nExclusion Criteria:\n\n* Subject withdraw from C87042 \\[NCT00308581\\] study\n* Subject who received treatment other than certolizumab pegol and other than medications permitted in C87042 \\[NCT00308581\\] study\n* Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment\n* Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks)","description":"Study-emergent adverse events are defined as treatment-emergent adverse events with an onset date on or after the first study drug administration date of this study but not later than 12 weeks (84 days) after last injection.\n\nResults are presented as the percentage of subjects with at least one treatment-emergent adverse event during this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance of Response at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals] Among the Subjects in Clinical Response at Baseline of This Study (Week 26 of Study C87042).","description":"Clinical response is defined as at least a 100 point decrease from Baseline of study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI).\n\nSubjects maintained their clinical response at Last Visit if they did not meet criteria for loss of response \\[CDAI score \\>150 points and a minimum increase in CDAI of 70 points versus Baseline of study C87042 (NCT00308581)\\] at 2 consecutive visits.\n\nA CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.\n\nResults are presented as the percentage of subjects maintaining response at Last visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals]","description":"Clinical response is defined as at least a 100 point decrease from Baseline of study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI).\n\nCDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.\n\nResults are presented as the percentage of subjects achieving clinical response at Last visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals]","description":"Remission is defined as a Crohn's Disease Activity Index (CDAI) score â‰¤ 150 points\n\nCDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.\n\nResults are presented as the percentage of subjects in remission at Last visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of Study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI) at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals]","description":"CDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-121.52","spread":"99.61"}]}]}]},{"type":"SECONDARY","title":"Time to Loss of Response After Baseline of Study C87042 (NCT00308581) on Subjects Who Were in Clinical Response at Baseline of This Study","description":"Clinical response at Baseline of this study of at least a 100 point decrease from Baseline of study C87042 in Crohn's Disease Activity Index (CDAI)\n\nLoss of response = both a CDAI score \\>150 points and a minimum increase in CDAI of 70 points versus Baseline (Week 26 of study C87042) as confirmed at 2 consecutive visits. Subjects losing response will be considered as having the event on the date of the first visit where response was lost. Subjects who discontinued the study without having lost response will be censored on the date of discontinuation (i.e. date of last visit performed).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"169.5","spread":"274.1"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Hospital Stay During the Treatment Period","description":"The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.\n\nResults are presented as the percentage of subjects with at least 1 hospital stay during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":"0.730"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Hospital Stay During the Follow-Up Period","description":"Follow-up period starts the day after the last injection up to 84 days after last injection.\n\nResults are presented as the percentage of subjects with at least 1 hospital stay during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":"0.578"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Hospital Stay During the During the Overall Period","description":"Overall period corresponds to both treatment and follow-up periods in C87046.\n\nResults are presented as the percentage of subjects with at least 1 hospital stay during the overall period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.6","spread":"0.953"}]}]}]},{"type":"SECONDARY","title":"Length of Hospital Stays During the Treatment Period","description":"The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.838","spread":"5.785"}]}]}]},{"type":"SECONDARY","title":"Length of Hospital Stays During the Follow-Up Period","description":"Follow-up period starts the day after the last injection up to 84 days after last injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.782","spread":"7.743"}]}]}]},{"type":"SECONDARY","title":"Length of Hospital Stays During the Overall Period","description":"Overall period corresponds to both treatment and follow-up periods in C87046.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.620","spread":"9.704"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Emergency Room Visit During the Treatment Period","description":"The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.\n\nResults are presented as the percentage of subjects with at least 1 emergency room visit during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"0.413"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Emergency Room Visit During the Follow-Up Period","description":"Follow-up period starts the day after the last injection up to 84 days after last injection.\n\nResults are presented as the percentage of subjects with at least 1 emergency room visit during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"0.265"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Emergency Room Visit During the Overall Period","description":"Overall period corresponds to both treatment and follow-up periods in C87046.\n\nResults are presented as the percentage of subjects with at least 1 emergency room visit during the overall period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"0.471"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Treatment Period","description":"The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.\n\nMedication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.\n\nResults are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.066"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"0.195"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"0.733"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"0.356"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":"2.889"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Follow-Up Period","description":"Follow-up period start the day after the last injection up to 84 days after last injection.\n\nMedication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.\n\nResults are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":"0.702"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"0.250"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"0.622"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.185"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"0.829"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Overall Period","description":"Overall period corresponds to both treatment and follow-up periods in C87046.\n\nMedication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.\n\nResults are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the overall period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":"0.716"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"0.337"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":"0.986"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"0.408"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":"2.974"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 General Concomitant Medication During the Treatment Period","description":"The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.\n\nResults are presented as the number of subjects who used at least 1 concomitant medication during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":"10.172"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 General Concomitant Medication During the Follow-Up Period","description":"Follow-up period start the day after the last injection up to 84 days after last injection.\n\nResults are presented as the number of subjects who used at least 1 concomitant medication during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":"3.395"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 General Concomitant Medication During the Overall Period","description":"Overall period corresponds to both treatment and follow-up periods in C87046.\n\nResults are presented as the number of subjects who used at least 1 concomitant medication during the overall period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":"10.948"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Concurrent Medical Procedure During the Treatment Period.","description":"The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.\n\nResults are presented as the number of subjects who had at least 1 concurrent medical procedure during the treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":"4.656"}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Concurrent Medical Procedure During the Follow-Up Period","description":"Follow-up period start the day after the last injection up to 84 days after last injection.\n\nResults are presented as the number of subjects who had at least 1 concurrent medical procedure during the follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of at Least 1 Concurrent Medical Procedure During the Overall Period","description":"Overall period corresponds to both treatment and follow-up periods in C87046.\n\nResults are presented as the number of subjects who had at least 1 concurrent medical procedure during the overall period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":73,"n":229},"commonTop":["Nasopharyngitis","Pyrexia","Headache","Abdominal pain","Arthralgia"]}}}